Point-of-Care Testing Devices
The U.S. point-of-care testing device market is growing with rising demand for rapid diagnostics, decentralized testing, and faster clinical decision-making across healthcare settings. Our research provides actionable insights into market size, technology adoption, competitive developments, and investment opportunities across molecular diagnostics, immunoassays, glucose testing, and infectious disease testing devices.
The U.S. multi-analyte point-of-care testing devices market is projected to expand from USD 7.84 billion in 2026 to USD 14.15 billion by 2032, registering a 10.34% CAGR. Demand is accelerated by emergency department overcrowding, central laboratory staffing shortages, and clinical needs for sub-ten-minute whole-blood diagnostic turnaround across critical care, cardiac triage, and syndromic molecular testing environments.
Read Report Details
The U.S. multiplex point-of-care testing devices market is projected to expand from USD 7.08 billion in 2026 to USD 14.85 billion by 2032 at a 13.14% CAGR. Growth is driven by rapid CLIA-waived molecular panel adoption across urgent care centers and emergency departments, automated sample-to-answer microfluidics, and aggressive clinical antimicrobial stewardship initiatives across the United States.
Read Report Details
The U.S. single-use point-of-care testing devices market is expanding from USD 18.06 billion in 2026 to USD 29.84 billion by 2032 at an 8.73% CAGR. Growth is driven by acute laboratory staffing shortages, rapid emergency department triage requirements, and expanding CLIA-waived testing across urgent care clinics, accelerating the adoption of disposable microfluidic, molecular, and electrochemical biosensor cartridges.
Read Report Details
The U.S. disposable point-of-care testing devices market is projected to expand from USD 19.15 billion in 2026 to USD 32.84 billion by 2032 at a 9.41% CAGR. Growth is driven by acute care decentralization, emergency department decompression, CLIA-waived test menu expansion, chronic cardiometabolic disease monitoring, and the clinical shift toward single-use microfluidic and rapid molecular diagnostic cartridges.
Read Report Details
The U.S. benchtop point-of-care testing devices market is projected to expand from USD 8.38 billion in 2026 to USD 14.15 billion by 2032, registering a 9.12% CAGR. Growth is driven by acute emergency triage demands, central laboratory staffing constraints, and rapid adoption of CLIA-waived microfluidic molecular PCR and high-sensitivity immunoassay platforms across hospital and ambulatory networks.
Read Report Details
The U.S. handheld point-of-care testing devices market is projected to expand from USD 13.12 billion in 2026 to USD 22.45 billion by 2032, advancing at a 9.37% CAGR. Growth is propelled by acute emergency triage optimization, hospital length-of-stay reduction, high-sensitivity cardiac troponin adoption, microfluidic lab-on-a-chip innovation, and decentralized diagnostic shifts across urgent care, critical care, and hospital-at-home networks.
Read Report Details
The U.S. Portable Point-of-Care Testing Devices Market is projected to expand from USD 19.15 billion in 2026 to USD 31.86 billion by 2032, registering an 8.86% CAGR. Growth is driven by acute emergency department overcrowding, central laboratory staffing constraints, rising cardiometabolic comorbidity prevalence, and rapid adoption of CLIA-waived microfluidic, electrochemical, and multiplex molecular diagnostics across decentralized outpatient care settings.
Read Report Details
The U.S. Rapid Point-of-Care Testing Devices Market is poised to grow from USD 19.05 billion in 2026 to USD 31.42 billion by 2032 at an 8.70% CAGR. Growth is fueled by decentralized clinical workflows, emergency triage acceleration, microfluidic advancements, rising chronic metabolic disease prevalence, and rapid adoption of CLIA-waived molecular and high-sensitivity immunoassay platforms across outpatient and acute settings.
Read Report Details
The U.S. CLIA-waived point-of-care testing devices market is projected to expand from USD 16.70 billion in 2026 to USD 27.13 billion by 2032, advancing at an 8.42% CAGR. Growth is driven by rapid decentralization across 330,000+ certificate of waiver sites, the adoption of CLIA-waived multiplex molecular systems, and value-based reimbursement incentives prioritizing immediate in-office diagnostic closure for acute and chronic conditions.
Read Report Details
The U.S. Point-of-Care Diagnostics Devices Market is undergoing rapid expansion, driven by the critical shift toward decentralized clinical testing, microfluidic innovation, and continuous physiological monitoring. Valued at $18.25 billion in 2026, the industry is projected to advance at a 9.13% CAGR, reaching $30.82 billion by 2032. Growth is anchored by high-sensitivity cardiac assays and CLIA-waived molecular platforms.
Read Report Details